-
Tytuł:
-
Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study.
-
Autorzy:
-
Mayama M; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Asano H; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Nomura E; Department of Obstetrics and Gynecology, Oji General Hospital, Tomakomai, Hokkaido, Japan.
Ihira K; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Nozaki A; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Kato T; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Konno Y; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Mitamura T; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Kobayashi N; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Takeda M; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Kudo M; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
Watari H; Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo.
-
Źródło:
-
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2020 Aug 04; Vol. 50 (8), pp. 882-888.
-
Typ publikacji:
-
Comparative Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Oxford : Oxford University Press
Original Publication: Tokyo, Foundation of Clinical Oncology.
-
MeSH Terms:
-
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Endometrial Neoplasms/*pathology
Neoplasm Recurrence, Local/*pathology
Aged ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/therapeutic use ; Disease-Free Survival ; Endometrial Neoplasms/drug therapy ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Paclitaxel/therapeutic use ; Probability ; Retrospective Studies ; Risk Factors ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: adjuvant chemotherapy; chemotherapy toxicity; endometrial neoplasms; mortality; propensity score
-
Substance Nomenclature:
-
BG3F62OND5 (Carboplatin)
P88XT4IS4D (Paclitaxel)
-
Entry Date(s):
-
Date Created: 20200424 Date Completed: 20200917 Latest Revision: 20200917
-
Update Code:
-
20240105
-
DOI:
-
10.1093/jjco/hyaa047
-
PMID:
-
32322873
-
Objective: This study compared the survival outcomes and the incidence of chemotherapy-related adverse events in endometrial cancer patients who received four and six cycles of adjuvant chemotherapy to examine the optimal number of adjuvant chemotherapy cycles.
Methods: A total of 112 patients with endometrial cancer with a high risk of recurrence were retrospectively enrolled; 46 patients received four cycles and 66 received six cycles of adjuvant chemotherapy. Between-group differences of overall survival, disease-free survival, hematological and non-hematological toxicities were analyzed. Baseline patient's background differences were assessed with inverse probability of treatment weighting using propensity score.
Results: Overall and disease-free survivals between the two groups were not significantly different. Paclitaxel + carboplatin, every 3-4 weeks was the most frequently used chemotherapy regimen in both groups. Patients in the six-cycle chemotherapy group developed neutropenia G4 or febrile neutropenia more frequently than those in the four-cycle group; odds ratio (95% confidence interval) is 4.07 (1.51-10.96). Peripheral sensory neuropathy was the most frequently observed non-hematological toxicity; the incidence of peripheral sensory neuropathy was not significantly different between four- and six-cycle chemotherapy group, P = 0.832. The result was same in the subgroup analysis in patients who received TC regimen, P = 0.455.
Conclusion: This study implies a possible benefit of fewer cycles of adjuvant chemotherapy in endometrial cancer patients with a high risk of recurrence because of the lower incidence of hematological toxicities without impairing survival outcomes.
(© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
